Pulmonx Co. (NASDAQ:LUNG - Get Free Report) Director Richard Ferrari sold 8,000 shares of the company's stock in a transaction dated Thursday, June 12th. The stock was sold at an average price of $3.16, for a total value of $25,280.00. Following the sale, the director now owns 87,024 shares of the company's stock, valued at approximately $274,995.84. This trade represents a 8.42% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.
Pulmonx Stock Performance
Pulmonx stock traded down $0.05 during trading hours on Monday, hitting $2.98. The stock had a trading volume of 161,296 shares, compared to its average volume of 310,711. The company has a 50-day moving average of $3.89 and a two-hundred day moving average of $5.81. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. The company has a market cap of $119.97 million, a PE ratio of -2.07 and a beta of 0.52. Pulmonx Co. has a fifty-two week low of $2.83 and a fifty-two week high of $9.37.
Pulmonx (NASDAQ:LUNG - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.36) EPS for the quarter, beating the consensus estimate of ($0.37) by $0.01. The firm had revenue of $22.54 million during the quarter, compared to analysts' expectations of $22.03 million. Pulmonx had a negative return on equity of 55.36% and a negative net margin of 67.31%. On average, equities research analysts anticipate that Pulmonx Co. will post -1.55 EPS for the current fiscal year.
Hedge Funds Weigh In On Pulmonx
Several large investors have recently added to or reduced their stakes in LUNG. Deerfield Management Company L.P. Series C acquired a new position in Pulmonx in the 4th quarter valued at approximately $10,421,000. Parkman Healthcare Partners LLC raised its holdings in Pulmonx by 194.4% in the 1st quarter. Parkman Healthcare Partners LLC now owns 611,875 shares of the company's stock valued at $4,118,000 after acquiring an additional 404,022 shares in the last quarter. Altium Capital Management LLC raised its holdings in Pulmonx by 63.0% in the 4th quarter. Altium Capital Management LLC now owns 815,000 shares of the company's stock valued at $5,534,000 after acquiring an additional 315,000 shares in the last quarter. Essex Investment Management Co. LLC acquired a new position in shares of Pulmonx in the 1st quarter worth approximately $2,041,000. Finally, Nuveen LLC acquired a new position in shares of Pulmonx in the 1st quarter worth approximately $1,336,000. Institutional investors and hedge funds own 91.04% of the company's stock.
Analyst Ratings Changes
LUNG has been the subject of several recent analyst reports. Morgan Stanley initiated coverage on Pulmonx in a research note on Monday, March 10th. They set an "equal weight" rating for the company. Citigroup decreased their target price on Pulmonx from $6.50 to $4.15 and set a "neutral" rating for the company in a research note on Thursday, May 22nd. D. Boral Capital restated a "buy" rating and set a $17.00 target price on shares of Pulmonx in a research note on Thursday, May 1st. Piper Sandler restated an "overweight" rating and set a $9.00 target price (down previously from $10.00) on shares of Pulmonx in a research note on Thursday, May 1st. Finally, Canaccord Genuity Group decreased their target price on Pulmonx from $16.00 to $15.00 and set a "buy" rating for the company in a research note on Thursday, May 1st. Three investment analysts have rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $11.53.
Check Out Our Latest Analysis on Pulmonx
About Pulmonx
(
Get Free Report)
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.
Recommended Stories
Before you consider Pulmonx, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pulmonx wasn't on the list.
While Pulmonx currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
